Bright Minds Biosciences Inc. Common Stock

Bright Minds Biosciences announced it will present at the Jefferies Global Healthcare Conference on June 3, 2026. The company also granted 109,000 stock options to directors, officers, and consultants at an exercise price of US$83.40 per share, vesting over four years.

B Group, Inc. initiated a new position in Bright Minds Biosciences by purchasing 67,500 shares worth approximately $5.43 million in Q1 2026. The investment signals confidence in the company's epilepsy drug pipeline, particularly BMB-101. Bright Minds is a pre-clinical biotech firm with a well-funded balance sheet (C$309.7 million in cash) and no ...

Bright Minds Biosciences (NASDAQ: DRUG) successfully closed a public offering of 1.945 million common shares at US$90 per share, raising US$175.05 million in gross proceeds. The company plans to use the net proceeds to fund clinical trials for drug candidates targeting absence seizures, DEE, Prader-Willi Syndrome, and BMB-105, along with R&D and ...

Bright Minds Biosciences priced an upsized public offering of 1,945,000 common shares at $90 per share for gross proceeds of $175.05 million. The company plans to use net proceeds to fund clinical trials for drug candidates targeting absence seizures, DEE, and Prader-Willi Syndrome, as well as phase 1 trials for BMB-105. The offering is expected ...

Bright Minds Biosciences strengthened its scientific advisory board with four experts in Prader-Willi Syndrome, launching a new investigational drug program targeting the rare genetic disorder. The company will evaluate existing and new treatment candidates, with initial Phase 1 studies focusing on safety and tolerability.